We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+5.01%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$531M
AUM Growth
-$19.6M
Cap. Flow
-$36.7M
Cap. Flow %
-6.9%
Top 10 Hldgs %
30.22%
Holding
139
New
9
Increased
20
Reduced
40
Closed
15

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$8.09M
2
SYK icon
Stryker
SYK
+$5.81M
3
AMSG
Amsurg Corp
AMSG
+$5.72M
4
ABMD
Abiomed Inc
ABMD
+$5.69M
5
HOLX
Hologic
HOLX
+$5.45M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$6.82M
2
BDX icon
Becton Dickinson
BDX
+$6.76M
3
BIIB icon
Biogen
BIIB
+$5.81M
4
SUPN icon
Supernus Pharmaceuticals
SUPN
+$4.91M
5
INSY
Insys Therapeutics, Inc.
INSY
+$4.49M

Sector Composition

Rank Sector Weight
1 Healthcare 92.67%
2 Financials 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TFX icon
76
Teleflex
TFX
$5.96B
$1.77M 0.33%
10,010
– –
PFE icon
77
Pfizer
PFE
$143B
$1.76M 0.33%
52,700
-63,240
-55% -$2.02M
BMY icon
78
Bristol-Myers Squibb
BMY
$124B
$1.69M 0.32%
23,000
-37,000
-62% -$2.61M
VAR
79
DELISTED
Varian Medical Systems, Inc.
VAR
$1.65M 0.31%
22,808
-19,386
-46% -$1.41M
ZLTQ
80
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$1.64M 0.31%
60,000
-15,000
-20% -$422K
HCSG icon
81
Healthcare Services Group
HCSG
$1.74B
$1.58M 0.3%
38,100
-11,900
-24% -$457K
LABU icon
82
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$617M
$1.56M 0.29%
2,759
+1,750
+173% +$1.1M
AGIO icon
83
Agios Pharmaceuticals
AGIO
$2.36B
$1.51M 0.28%
36,000
-18,000
-33% -$889K
RDUS
84
DELISTED
Radius Health, Inc.
RDUS
$1.47M 0.28%
40,000
– –
ACAD icon
85
Acadia Pharmaceuticals
ACAD
$4.38B
$1.46M 0.27%
45,000
– –
INO icon
86
Inovio Pharmaceuticals
INO
$92.1M
$1.43M 0.27%
12,917
-9,166
-42% -$1.11M
JUNO
87
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.42M 0.27%
37,000
– –
RARE icon
88
Ultragenyx Pharmaceutical
RARE
$2.88B
$1.37M 0.26%
28,000
+18,000
+180% +$1.16M
ALNY icon
89
Alnylam Pharmaceuticals
ALNY
$35.7B
$1.33M 0.25%
24,000
– –
EXEL icon
90
Exelixis
EXEL
$14.1B
$1.33M 0.25%
170,000
– –
BLUE
91
DELISTED
bluebird bio
BLUE
$1.25M 0.24%
2,239
– –
ALR
92
DELISTED
Alere Inc
ALR
$1.25M 0.24%
+30,000
New +$1.3M
WMGI
93
DELISTED
Wright Medical Group Inc
WMGI
$1.22M 0.23%
70,309
– –
PRTA icon
94
Prothena Corp
PRTA
$453M
$1.08M 0.2%
31,000
– –
LH icon
95
Labcorp
LH
$23.2B
$1.04M 0.2%
9,312
-2,328
-20% -$251K
AAC
96
DELISTED
AAC Holdings
AAC
$1.03M 0.19%
+45,000
New +$917K
DVA icon
97
DaVita
DVA
$15.2B
$1M 0.19%
13,000
-7,000
-35% -$529K
EVHC
98
DELISTED
Envision Healthcare Holdings Inc
EVHC
$989K 0.19%
+13,026
New +$925K
ABBV icon
99
AbbVie
ABBV
$450B
$929K 0.17%
15,000
– –
CPHD
100
DELISTED
Cepheid Inc
CPHD
$923K 0.17%
+30,000
New +$907K
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2016 Portfolio in Review

As of Q2 2016, Bellevue Group held 139 positions worth $531M, down 3.6% from $551M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group withdrew a net $36.7M in Q2 2016, closing 15 positions and reducing 40 holdings. Its most notable exit was Insys Therapeutics, Inc., an estimated $4.49M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Financials.

Against the trend, Bellevue Group opened a new position in Allergan plc worth $8.11M.

  • Bellevue Group's largest Q2 2016 buy was Allergan plc: 35,100 shares worth $8.11M.
  • Bellevue Group added most to Stryker in Q2 2016, an estimated $5.81M increase.
  • Bellevue Group's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $6.82M.
  • Bellevue Group fully exited Insys Therapeutics, Inc. in Q2 2016, selling an estimated $4.49M.
  • Bellevue Group's ten largest holdings make up 30% of its $531M portfolio in Q2 2016.
  • Bellevue Group opened 9 new positions and closed 15 in Q2 2016.
  • Bellevue Group's portfolio value fell 3.6% quarter-over-quarter to $531M.

Based on Bellevue Group's 13F filing for Q2 2016, filed 12 Aug 2016.